Skip to main content
SpringerLink
Log in

Neurodegenerative und Demenzielle Erkrankungen

  • Chapter
  • First Online:
PET/CT-Atlas

  • 132 Accesses

Zusammenfassung

Neurodegenerative Erkrankungen sind auf Grund der demografischen Alterung von großer epidemiologischer Bedeutung. Hierzu zählen insbesondere Demenzerkrankungen, die durch einen Verlust kognitiver Fähigkeiten und eine Beeinträchtigung der Alltagsbewältigung charakterisiert sind. Die Betroffenen sind zunehmend auf Hilfe durch Dritte angewiesen, so dass Demenzerkrankungen auch Angehörige und Familien stark belasten. Gegenwärtig geht man für Deutschland von 1,6 Millionen Demenzbetroffenen aus, der Anstieg bis 2050 wird auf etwa 3 Millionen Betroffene geschätzt. Häufigste Ursache ist die Alzheimer Krankheit (AD), die in etwa 70 % der Fälle als Haupt- oder Teilursache einer Demenz in Betracht kommt. Weitere wesentliche Risikofaktoren sind andere neurodegenerative und zerebrovaskuläre Erkrankungen, kardiovaskuläre und pulmonale Erkrankungen, aber auch soziodemografische Faktoren, wie geringe Bildung, niedriges Einkommen und soziale Isolation. Der molekularen Bildgebung kommt heute bereits eine wichtige Rolle bei der Früh- und Differentialdiagnose dementieller Erkrankungen zu. Diese Bedeutung wird weiter zunehmen, wenn ab 2024 erste Amyloid-senkende Therapien mit Anti-Amyloid-Antikörpern in Europa zugelassen werden. Neben einer Liquorpunktion wird die Amyloid-PET dann wesentlich zur Therapieentscheidung und zum Therapiemonitoring beitragen.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  1. Organization WH (2021) Dementia. World Health Organization, Geneva

    Google Scholar 

  2. Arnoldussen IAC, Gustafson DR, Leijsen EMC, de Leeuw FE, Kiliaan AJ (2019) Adiposity is related to cerebrovascular and brain volumetry outcomes in the RUN DMC study. Neurology 93:e864–e878

    Article  PubMed  Google Scholar 

  3. Livingston G, Huntley J, Sommerlad A et al (2020) Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet 396:413–446

    Article  PubMed  PubMed Central  Google Scholar 

  4. Jack CR Jr., Bennett DA, Blennow K et al (2018) NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement 14:535–562

    Article  PubMed  Google Scholar 

  5. Jack CR Jr., Bennett DA, Blennow K et al (2016) A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology 87:539–547

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Dimou E, Booij J, Rodrigues M et al (2009) Amyloid PET and MRI in Alzheimer’s disease and mild cognitive impairment. Curr Alzheimer Res 6:312–319

    Article  CAS  PubMed  Google Scholar 

  7. Grothe MJ, Barthel H, Sepulcre J et al (2017) In vivo staging of regional amyloid deposition. Neurology 89:2031–2038

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Teipel SJ, Temp AGM, Levin F, Dyrba M, Grothe MJ, Alzheimer’s Disease Neuroimaging I (2021) Association of PET-based stages of amyloid deposition with neuropathological markers of Abeta pathology. Ann Clin Transl Neurol 8:29–42

    Article  CAS  PubMed  Google Scholar 

  9. Rabinovici GD, Gatsonis C, Apgar C et al (2019) Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia. JAMA 321:1286–1294

    Article  PubMed  PubMed Central  Google Scholar 

  10. Zhang, K., Mizuma, H., Zhang, X., Takahashi, K., Jin, C., Song, F., Gao, Y., Kanayama, Y., Wu, Y., Li, Y., Ma, L., Tian, M., Zhang, H., and Watanabe, Y. (2021). PET imaging of neural activity, beta-amyloid, and tau in normal brain aging. Eur J Nucl Med Mol Imaging 48:3859-3871

    Google Scholar 

  11. Rice L, Bisdas S (2017) The diagnostic value of FDG and amyloid PET in Alzheimer’s disease—A systematic review. Eur J Radiol 94:16–24

    Article  PubMed  Google Scholar 

  12. Wiley CA, Lopresti BJ, Venneti S et al (2009) Carbon 11-labeled Pittsburgh Compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease. Arch Neurol 66:60–67

    Article  PubMed  PubMed Central  Google Scholar 

  13. Herholz K, Weisenbach S, Zundorf G et al (2004) In vivo study of acetylcholine esterase in basal forebrain, amygdala, and cortex in mild to moderate Alzheimer disease. Neuroimage 21:136–143

    Article  CAS  PubMed  Google Scholar 

  14. Sabri O, Meyer PM, Graf S et al (2018) Cognitive correlates of alpha4beta2 nicotinic acetylcholine receptors in mild Alzheimer’s dementia. Brain 141:1840–1854

    Article  PubMed  PubMed Central  Google Scholar 

  15. Rascovsky K, Hodges JR, Knopman D et al (2011) Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 134:2456–2477

    Article  PubMed  PubMed Central  Google Scholar 

  16. Gorno-Tempini ML, Hillis AE, Weintraub S et al (2011) Classification of primary progressive aphasia and its variants. Neurology 76:1006–1014

    Article  PubMed  PubMed Central  Google Scholar 

  17. Davison CM, O’Brien JT (2014) A comparison of FDG-PET and blood flow SPECT in the diagnosis of neurodegenerative dementias: a systematic review. Int J Geriatr Psychiatry 29:551–561

    Article  PubMed  Google Scholar 

  18. Lu J, Huang L, Lv Y et al (2021) A disease-specific metabolic imaging marker for diagnosis and progression evaluation of semantic variant primary progressive aphasia. Eur J Neurol 28:2927–2939

    Article  PubMed  Google Scholar 

  19. Minoshima S, Mosci K, Cross D, Thientunyakit TB (2021) [F-18]FDG PET for Clinical Dementia Workup: Differential Diagnosis of Alzheimer’s Disease and Other Types of Dementing Disorders. Semin Nucl Med 51:230–240

    Article  PubMed  Google Scholar 

  20. Nestor PJ, Balan K, Cheow HK et al (2007) Nuclear imaging can predict pathologic diagnosis in progressive nonfluent aphasia. Neurology 68:238–239

    Article  CAS  PubMed  Google Scholar 

  21. Whitwell JL, Duffy JR, Strand EA et al (2015) Clinical and neuroimaging biomarkers of amyloid-negative logopenic primary progressive aphasia. Brain Lang 142:45–53

    Article  PubMed  PubMed Central  Google Scholar 

  22. Botha H, Mantyh WG, Murray ME et al (2018) FDG-PET in tau-negative amnestic dementia resembles that of autopsy-proven hippocampal sclerosis. Brain 141:1201–1217

    Article  PubMed  PubMed Central  Google Scholar 

  23. Buciuc M, Botha H, Murray ME et al (2020) Utility of FDG-PET in diagnosis of Alzheimer-related TDP-43 proteinopathy. Neurology 95:e23–e34

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Grothe MJ, Lange C, Nho K et al (2019) IC-P-063: A topographic imaging biomarker of TDP43 pathology in amnestic dementia based on autopsy-derived FDG-PET patterns. Paper presented at: Alzheimer’s Association Intenational Conference 2019, Los Angeles

    Google Scholar 

  25. Nobili F, Arbizu J, Bouwman F et al (2018) European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain (18) F-fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus. Eur J Neurol 25:1201–1217

    Article  CAS  PubMed  Google Scholar 

  26. Hoglinger GU, Respondek G, Stamelou M et al (2017) Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Mov Disord 32:853–864

    Article  PubMed  PubMed Central  Google Scholar 

  27. Garraux G, Salmon E, Peigneux P et al (2000) Voxel-based distribution of metabolic impairment in corticobasal degeneration. Mov Disord 15:894–904

    Article  CAS  PubMed  Google Scholar 

  28. Laureys S, Salmon E, Garraux G et al (1999) Fluorodopa uptake and glucose metabolism in early stages of corticobasal degeneration. J Neurol 246:1151–1158

    Article  CAS  PubMed  Google Scholar 

  29. Taswell C, Villemagne VL, Yates P et al (2015) 18F-FDG PET Improves Diagnosis in Patients with Focal-Onset Dementias. J Nucl Med 56:1547–1553

    Article  CAS  PubMed  Google Scholar 

  30. Sha SJ, Ghosh PM, Lee SE et al (2015) Predicting amyloid status in corticobasal syndrome using modified clinical criteria, magnetic resonance imaging and fluorodeoxyglucose positron emission tomography. Alzheimers Res Ther 7:8

    Article  PubMed  PubMed Central  Google Scholar 

  31. Pardini M, Huey ED, Spina S et al (2019) FDG-PET patterns associated with underlying pathology in corticobasal syndrome. Neurology 92:e1121–e1135

    Article  PubMed  PubMed Central  Google Scholar 

  32. Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE (1995) A diagnostic approach in Alzheimer’s disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med 36:1238–1248

    CAS  PubMed  Google Scholar 

  33. Smailagic N, Lafortune L, Kelly S, Hyde C, Brayne C (2018) 18F-FDG PET for Prediction of Conversion to Alzheimer’s Disease Dementia in People with Mild Cognitive Impairment: An Updated Systematic Review of Test Accuracy. J Alzheimers Dis 64:1175–1194

    Article  PubMed  PubMed Central  Google Scholar 

  34. Minoshima S, Koeppe RA, Frey KA, Kuhl DE (1994) Anatomic standardization: linear scaling and nonlinear warping of functional brain images. J Nucl Med 35:1528–1537

    CAS  PubMed  Google Scholar 

  35. Johnson KA, Minoshima S, Bohnen NI et al (2013) Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association. J Nucl Med 54:476–490

    Article  CAS  PubMed  Google Scholar 

  36. Altomare D, Ferrari C, Festari C et al (2018) Quantitative appraisal of the Amyloid Imaging Taskforce appropriate use criteria for amyloid-PET. Alzheimers Dement 14:1088–1098

    Article  PubMed  Google Scholar 

  37. Morris JC, Roe CM, Grant EA et al (2009) Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol 66:1469–1475

    Article  PubMed  PubMed Central  Google Scholar 

  38. Villemagne VL, Pike KE, Chetelat G et al (2011) Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. Ann Neurol 69:181–192

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Segovia F, Gomez-Rio M, Sanchez-Vano R et al (2018) Usefulness of dual-point Amyloid PET scans in appropriate use criteria: a multicenter study. J Alzheimers Dis 65:765–779

    Article  CAS  PubMed  Google Scholar 

  40. Daerr S, Brendel M, Zach C et al (2017) Evaluation of early-phase [(18)F]-florbetaben PET acquisition in clinical routine cases. Neuroimage Clin 14:77–86

    Article  PubMed  Google Scholar 

  41. Belohlavek O, Jaruskova M, Skopalova M, Szarazova G, Simonova K (2019) Improved beta-amyloid PET reproducibility using two-phase acquisition and grey matter delineation. Eur J Nucl Med Mol Imaging 46:297–303

    Article  CAS  PubMed  Google Scholar 

  42. Zhang S, Smailagic N, Hyde C et al (2014) (11)C-PIB-PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD010386.pub2

    Article  PubMed  PubMed Central  Google Scholar 

  43. Martinez G, Vernooij RW, Fuentes Padilla P, Zamora J, Flicker L, Bonfill Cosp X (2017) 18F PET with flutemetamol for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD012884

    Article  PubMed  PubMed Central  Google Scholar 

  44. Martinez G, Vernooij RW, Fuentes Padilla P, Zamora J, Bonfill Cosp X, Flicker L (2017) 18F PET with florbetapir for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD012216.pub2

    Article  PubMed  PubMed Central  Google Scholar 

  45. Martinez G, Vernooij RW, Fuentes Padilla P, Zamora J, Flicker L, Bonfill Cosp X (2017) 18F PET with florbetaben for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD012883

    Article  PubMed  PubMed Central  Google Scholar 

  46. Teipel, S.J., Dyrba, M., Chiesa, P.A., Sakr, F., Jelistratova, I., Lista, S., Vergallo, A., Lemercier, P., Cavedo, E., Habert, M.O., Dubois, B., Hampel, H., Grothe, M.J., Group, I.N.-P.S., and For the Alzheimers Disease Neuroimaging, I. (2020). In vivo staging of regional amyloid deposition predicts functional conversion in the preclinical and prodromal phases of Alzheimer’s disease. Neurobiol Aging 93:98-108

    Google Scholar 

  47. Teipel SJ, Spottke A, Boecker H, Daamen M, Graf E, Sahlmann J, Buchert R, Mohnike W, Mohnike K, Kurth J, Jessen F, Krause BJ (2023). Patient-related benefits of amyloid PET imaging in dementia: Rationale and design of the German randomized coverage with evidence development study ENABLE. Alzheimers Dement (N Y) TRCI 9

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Deutsches Zentrum für Neurodegenerative Erkrankungen e. V. (DZNE), Rostock, Deutschland

    Prof. Dr. med. Stefan Teipel

  2. Universitätsmedizin Rostock, Klinik und Poliklinik für Nuklearmedizin, Rostock, Deutschland

    Priv.-Doz. Dr.-Ing. Jens Kurth

  3. Zentrum für Nervenheilkunde Klinik und Poliklinik für Neurologie, Universitätsmedizin Rostock, Rostock, Deutschland

    Prof. Dr. med. Johannes Prudlo

  4. Diagnostisch Therapeutisches Zentrum, Berlin, Deutschland

    Prof. Dr. med. Wolfgang Mohnike

  5. Universitätsmedizin Rostock, Klinik und Poliklinik für Nuklearmedizin, Rostock, Deutschland

    Prof. Dr. med. Bernd Joachim Krause

Authors
  1. Prof. Dr. med. Stefan Teipel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Priv.-Doz. Dr.-Ing. Jens Kurth
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Prof. Dr. med. Johannes Prudlo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Prof. Dr. med. Wolfgang Mohnike
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Prof. Dr. med. Bernd Joachim Krause
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stefan Teipel .

Editor information

Editors and Affiliations

  1. DTZ, Diagnostic and Treatment Centre Berlin, Berlin, Deutschland

    Wolfgang Mohnike

  2. DTZ, Diagnostic and Treatment Centre Berlin, Berlin, Deutschland

    Konrad Mohnike

  3. DTZ, Diagnostic and Treatment Centre Berlin, Berlin, Berlin, Deutschland

    Matthias Lampe

Rights and permissions

Reprints and permissions

Copyright information

© 2024 Der/die Autor(en), exklusiv lizenziert an Springer-Verlag GmbH, DE, ein Teil von Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Teipel, S., Kurth, J., Prudlo, J., Mohnike, W., Krause, B.J. (2024). Neurodegenerative und Demenzielle Erkrankungen. In: Mohnike, W., Mohnike, K., Lampe, M. (eds) PET/CT-Atlas. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-67192-4_29

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-67192-4_29

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-67191-7

  • Online ISBN: 978-3-662-67192-4

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation